Table 1 Patient demographics and baseline characteristics for all prospective patients based on index therapy
All prospective patients (N = 1356) | IPI-treated cohort | Non-IPI–treated cohort | |||
|---|---|---|---|---|---|
IPI-noOther (n = 780) | IPI-Other (n = 314) | Other-Other (n = 205) | Other-IPI (n = 57) | ||
Median age, years (range) | 64 (22–90) | 65 (22–90) | 62 (25–88) | 63 (24–89) | 60 (27–84) |
Sex, no. (%) | |||||
Male | 819 (60) | 483 (62) | 178 (57) | 118 (58) | 40 (70) |
Female | 537 (40) | 297 (38) | 136 (43) | 87 (42) | 17 (30) |
Race, no. (%) | |||||
White | 1300 (96) | 746 (96) | 300 (96) | 200 (98) | 54 (95) |
Asian | 3 (< 1) | 2 (< 1) | 0 | 0 | 1 (2) |
Other | 7 (1) | 6 (1) | 1 (< 1) | 0 | 0 |
Not specified | 46 (3) | 26 (3) | 13 (4) | 5 (2) | 2 (4) |
Geographic region, no. (%) | |||||
Europe | 1061 (78) | 641 (82) | 231 (74) | 149 (73) | 40 (70) |
North America | 170 (13) | 67 (9) | 64 (20) | 29 (14) | 10 (18) |
Rest of world | 125 (9) | 72 (9) | 19 (6) | 27 (13) | 7 (12) |
Time on study,a months | |||||
Mean (SD) | 10 (11) | 9 (10) | 14 (11) | 9 (10) | 13 (9) |
Median (range) | 6 (0–50) | 5 (0–46) | 10 (1–39) | 5 (0–38) | 9 (2–50) |
Previous systemic therapy for advanced melanoma, no. (%) | |||||
Yes | 1064 (78) | 619 (79) | 233 (74) | 169 (82) | 43 (75) |
No | 292 (22) | 161 (21) | 81 (26) | 36 (18) | 14 (25) |
BRAF mutation status, no. (%) | |||||
Mutant | 542 (40) | 262 (34) | 135 (43) | 116 (57) | 29 (51) |
Wild-type | 743 (55) | 471 (60) | 162 (52) | 84 (41) | 26 (46) |
Inconclusive/unknown | 12 (1) | 8 (1) | 3 (1) | 1 (< 1) | 0 |
Missing | 59 (4) | 39 (5) | 14 (4) | 4 (2) | 2 (4) |
ECOG PS, no. (%) | |||||
0 | 470 (35) | 274 (35) | 134 (43) | 47 (23) | 15 (26) |
1 | 328 (24) | 208 (27) | 59 (19) | 48 (23) | 13 (23) |
2 | 63 (5) | 35 (4) | 5 (2) | 22 (11) | 1 (2) |
3 | 13 (1) | 3 (< 1) | 0 | 8 (4) | 2 (4) |
4 | 2 (< 1) | 1 (< 1) | 0 | 1 (< 1) | 0 |
Missing | 480 (35) | 259 (33) | 116 (37) | 79 (39) | 26 (46) |
Disease stage, no. (%) | |||||
Stage III | 44 (3) | 26 (3) | 10 (3) | 3 (1) | 5 (9) |
Stage IV | 1312 (97) | 754 (97) | 304 (97) | 202 (99) | 52 (91) |
Metastases stage, no. (%) | |||||
M0 | 43 (3) | 25 (3) | 10 (3) | 3 (1) | 5 (9) |
M1a | 150 (11) | 85 (11) | 41 (13) | 22 (11) | 2 (4) |
M1b | 247 (18) | 144 (18) | 69 (22) | 29 (14) | 5 (9) |
M1c | 638 (47) | 382 (49) | 143 (46) | 85 (41) | 28 (49) |
CNS | 278 (21) | 144 (18) | 51 (16) | 66 (32) | 17 (30) |
CNS metastases,b no. (%) | |||||
Symptomatic | 85 (31) | 42 (29) | 16 (31) | 22 (33) | 5 (29) |
Asymptomatic | 193 (69) | 102 (71) | 35 (69) | 44 (67) | 12 (71) |
LDH status at study entry, no. (%) | |||||
Normal | 542 (40) | 298 (38) | 159 (51) | 64 (31) | 21 (37) |
Elevated or outside of normal | 531 (39) | 310 (40) | 105 (33) | 92 (45) | 24 (42) |
Not assessed | 283 (21) | 172 (22) | 50 (16) | 49 (24) | 12 (21) |